NetworkNewsBreaks – Satsuma Pharmaceuticals, Inc. (NASDAQ: STSA) Featured in Mizuho Securities Research Report
Satsuma Pharmaceuticals, Inc. (NASDAQ: STSA) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Satsuma provided a 3Q 2020 business update after the close. Most importantly, management is still analyzing full data from the EMERGE trial for STS101, their DHE nasal powder for the acute treatment of migraine headaches, after top-line data released in September showed STS101 did not meet the co-primary endpoints of the study. Management will provide an update of their next steps by early 2021. Detailed trial data or updates on potential alternatives the company may pursue could lead…







